Retraction highlights integrity issues with data on Notch‐1 involvement in colon cancer, indicating concerns with regorafenib therapy.
RETRACTION: G. Mirone, S. Perna, A. Shukla, G. Marfe, “Involvement of Notch‐1 in Resistance to Regorafenib in Colon Cancer Cells,” Journal of Cellular Physiology 231, no. 5 (2015): 1097‐1105, https://doi.org/10.1002/jcp.25206 . The above article, published online on 30 September 2015 in Wiley Online Library ( wileyonlinelibrary.com ), has been retracted by agreement between the journal Editor‐in‐Chief, Robert Heath; and Wiley Periodicals LLC. The retraction has been agreed due to concerns raised by the third party, which revealed inappropriate figure duplications in Figure 5B and Figure 7D, by different groups of authors in different articles. In addition, there are inconsistencies in Figure 2B. The corresponding author has responded in accordance with the concerns and provided the original western blots for Figure 5B and explanation for Figure 2B. However, data issues were found in the last authors' other articles and the Editor‐in‐Chief now has lost confidence in the integrity and reliability of the full body of data presented in the article and consider the conclusions of this manuscript substantially compromised. The authors were informed of the retraction.
No takes yet. Share an insight, caveat, or question.
A 2025 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: